Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer killing virus shows early promise against colorectal cancer

07.06.2005


A single injection of a genetically engineered virus has shown promise as a treatment for patients with colorectal cancer that has spread to the liver, according to preliminary results reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

In their phase I study, Professor Nancy Kemeny from Memorial Sloan-Kettering Cancer Center in New York, and colleagues tested an oncolytic Herpes simplex virus (oHSV). These viruses selectively kill cancer cells while sparing normal tissue and are considered a promising new strategy to treat tumors. They have already been shown to be effective against chemotherapy-resistant cancers in preclinical studies. The specific strain of virus investigated by Prof. Kemeny’s team was NV1020, weakened and altered form of herpes simplex virus type-1, the virus associated with cold sores.

In 12 patients with colorectal adenocarcinoma that had spread to the liver and proven resistant to first-line chemotherapy, the scientists tested increasing doses of NV1020 delivered via a single 10-minute arterial infusion. Treatment was followed by regional chemotherapy. Patients in the study generally experienced mild or moderate adverse events associated with the treatment, the researchers found, although self-limiting serious adverse events experienced by three patients were considered possibly or probably related to NV1020. These events comprised a temporary increase of gamma-glutamyl transpeptidase--a sign of liver disease--12 hours after treatment in a patient with a history of hepatitis, a case of gastroenteritis, and a case of mild leukocytosis considered due to a respiratory infection.



None of the patients showed any signs of disseminated herpes infection; the virus was detected in just one saliva sample and two blood samples from one asymptomatic patient who received the highest dose. "Our primary aim in this study was to test the safety of the virus," Professor Kemeny said. "We were pleased to see that the virus could be administered safely in the hepatic artery without significant effects on the normal liver function. We were also excited that CEA reductions were seen in patients after virus administration and before regional therapy."

So far, the overall median survival time of the 12 patients is 23 months with one patient still alive at 30 months post therapy. "These results are very promising," Professor Kemeny says. "The median survival time we saw among our patients was higher than you might expect among this group of patients. However, all were treated with hepatic arterial therapy and systemic therapy after the virus therapy."

The next step for the investigators is to use multiple doses of the virus since there are preclinical data to indicate that herpes oncolytic viruses work best when administered in multiple doses.

Commenting on the report, Professor Hans Joachim Schmoll, of Martin-Luther-Universität Halle-Wittenberg in Germany, noted that locoregional chemotherapy is an excellent approach for delivering active drugs in metastatic colorectal cancer with liver metastases. "The application of the tumoricidal virus by the arterial route could be of high interest since higher viral load will be delivered to the liver metastases," he said.

"These results represent the first time that an anti-tumor response has been seen after intra-arterial or systemic application of a tumor killing virus", he added. "Therefore, the study is highly interesting and promising in terms of giving the basis for further trials with genetic-modified tumoricidal viral constructs."

Gracemarie Bricalli | EurekAlert!
Further information:
http://www.esmo.org

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The fastest light-driven current source

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

Graphene is up to the job

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Nerves control the body’s bacterial community

26.09.2017 | Life Sciences

Four elements make 2-D optical platform

26.09.2017 | Physics and Astronomy

Goodbye, login. Hello, heart scan

26.09.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>